Corporate News: Scancell Shares Decline Amid Market Volatility

Scancell Holdings plc (SCLP.L) experienced a decline of 3.01 % during the 24‑hour trading window that concluded at 05:53 AM Central European Time on Saturday, 24 April 2026. At the close of that session, one share of Scancell traded at approximately GBP 91 on major exchanges. The company’s current free float amounts to 135.7 million shares, and its market capitalisation stands at GBP 165.4 million. In the previous 24 hours, trading volume amounted to roughly GBP 7.9 million.

Recent Performance

Over the last month, Scancell’s share price has fallen by 7.01 %. The 200‑day simple moving average (SMA) is positioned at GBP 134.51, providing a technical benchmark against which the current price can be gauged. The highest level the stock has reached in the past 52 weeks was GBP 295 on 19 May 2026, whereas the 52‑week low fell to GBP 89.5 on 21 October 2026.

Comparative Activity in the Sector

The performance of related stocks during the same 24‑hour period provides context for the broader market sentiment:

  • Physitrack (PTRK.ST): down 0.4 %, trading at SEK 12.4; market capitalisation SEK 19.1 million.
  • Trifast (TRI.L): down 1.18 %, trading at GBP 80.2; market capitalisation GBP 196.4 million.
  • Northern 3 Vct -Ord (NTN.L): unchanged, trading at GBP 82; market capitalisation GBP 193.8 million.
  • Focusrite (TUNE.L): down 0.43 %, trading at GBP 227.5; market capitalisation GBP 182.4 million.
  • Quartix (QTX.L): unchanged, trading at GBP 230; market capitalisation GBP 192.7 million; price‑earnings ratio 17.46.

These movements reflect a mix of modest declines and stability across the sector, suggesting that Scancell’s drop may be driven more by company‑specific factors than by broad market forces.

Company Overview

Scancell Holdings plc is a London‑based biopharmaceutical company that focuses on the development of vaccines derived from a proprietary human monoclonal antibody platform. By harnessing this technology, Scancell seeks to create bespoke immunotherapies capable of targeting a range of diseases. The company is listed on the London Stock Exchange and maintains an online presence at www.scancell.co.uk .